文献速递淋巴瘤

维布妥昔单抗累积剂量对晚期霍奇金淋巴瘤一线治疗结局的影响

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

该真实世界回顾性分析纳入2010年1月至2022年4月接受A+AVD一线治疗的179例III或IV期经典型霍奇金淋巴瘤患者,中位年龄37岁,46%为高危国际预后评分。中位随访27.4个月(95%CI 24.8-29),12个月无进展生存率为90.3%(95%CI 85.9-95.0);累积剂量对无进展生存的影响不显著(P=.15)。

要点

  • 91%的患者接受了6周期AVD,55%未达到预期的维布妥昔单抗累积剂量。
  • 28%的患者接受的累积剂量为计划量的三分之二或更少。
  • 累积剂量对无进展生存的影响不显著(P=.15),高累积剂量与不良事件增加无显著关联。

核心结论

  • 在真实世界经验中,A+AVD是晚期经典型霍奇金淋巴瘤的高效治疗,包括维布妥昔单抗大幅减量的患者。

研究设计与样本

  • 真实世界回顾性分析,纳入2010年1月至2022年4月接受一线A+AVD治疗的179例III或IV期经典型霍奇金淋巴瘤患者。
  • 治疗为每28天周期第1天和第15天静脉给予最多1.2 mg/kg维布妥昔单抗和标准剂量AVD,最多6周期。

主要发现

  • 治疗时中位年龄37岁,46%的患者为高危国际预后评分。
  • 91%的患者接受了6周期AVD;55%未接受预期的维布妥昔单抗累积剂量;28%接受的累积剂量为计划量的三分之二或更少。
  • 中位随访27.4个月(95%CI 24.8-29),中位无进展生存未达到,12个月无进展生存率为90.3%(95%CI 85.9-95.0)。
  • 累积剂量对无进展生存的影响不显著(P=.15),高累积剂量与不良事件增加无显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). However, there are minimal available data regarding the frequency of dose reductions or omission of BV during curative therapy and the potential impact on patient outcomes. In a real-world analysis, we retrospectively reviewed the characteristics and outcomes of 179 patients with stage III or IV cHL treated with frontline A + AVD from January 2010 to April 2022. Treatment consisted of up to 1.2 mg/kg of BV and standard dose AVD IV on days 1 and 15 of each 28-day cycle for up to 6 cycles. At the time of treatment, the median patient age was 37 years, and a high-risk International Prognostic Score was observed in 46% of patients. Overall, 91% of patients received 6 cycles of AVD; 55% of patients did not receive the intended cumulative dose of BV (CDB); 28% of patients received two-thirds or less than the planned CDB. At a median follow-up time of 27.4 months (95% confidence interval [CI], 24.8-29), the median progression-free survival (PFS) was not reached, and the 12-month PFS was 90.3% (95% CI, 85.9-95.0). The impact of CDB on PFS was not significant (P = .15), nor was high CDB significantly associated with increased adverse events. In real-world experience, A + AVD is a highly effective treatment for patients with advanced-stage cHL, including for patients with prominent dose reductions of BV.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Steiner RE, Hwang SR, Khurana A, et al. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Adv. 2023. PMID: 37603594. doi:10.1182/bloodadvances.2023010700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。